Form 4 holding
10%+ Owner
SpringWorks Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 5,599,842
- Estimated value
- $232,561,438
- Report date
- 12 Sep 2022
- Price
- $41.53
- Ownership
- Indirect
ORBIMED ADVISORS LLC
Insider Reports History
- Location
- New York, NY
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by ORBIMED ADVISORS LLC:
Form 4 holding
Director, 10%+ Owner
Enliven Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 7,663,349
- Estimated value
- $169,666,547
- Report date
- 16 May 2024
- Price
- $22.14
- Ownership
- Indirect
Form 4 holding
Director
Sionna Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 2,671,822
- Estimated value
- $123,491,612
- Report date
- 11 May 2026
- Price
- $46.22
- Ownership
- Indirect
Form 4 holding
Director
Verona Pharma plc
- Security class
- Ordinary Shares
- Shares / value
- 3,777,778
- Estimated value
- $75,555,560
- Report date
- 15 May 2023
- Price
- $20.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Third Harmonic Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 5,779,071
- Estimated value
- $59,522,120
- Report date
- 19 Sep 2022
- Price
- $10.30
- Ownership
- Indirect
Form 4 holding
10%+ Owner
NeuroPace Inc
- Security class
- Common Stock
- Shares / value
- 3,238,199
- Estimated value
- $51,616,892
- Report date
- 14 May 2025
- Price
- $15.94
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Corvus Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 7,165,006
- Estimated value
- $29,796,393
- Report date
- 27 Jun 2025
- Price
- $4.16
- Ownership
- Indirect
Form 4 holding
10%+ Owner
89bio, Inc.
- Security class
- Common Stock
- Shares / value
- 1,829,436
- Estimated value
- $21,093,397
- Report date
- 26 Jan 2022
- Price
- $11.53
- Ownership
- Indirect
Form 4 holding
10%+ Owner
TELA Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 2,407,242
- Estimated value
- $10,928,879
- Report date
- 02 Jul 2024
- Price
- $4.54
- Ownership
- Indirect
Form 4 holding
Director
Venetian-1 Acquisition Corp.
- Security class
- Common Stock
- Shares / value
- 2,677,256
- Estimated value
- $10,709,024
- Report date
- 01 Nov 2024
- Price
- $4.00
- Ownership
- Indirect
Form 4 holding
Director
Disc Medicine, Inc.
- Security class
- Common Stock
- Shares / value
- 186,541
- Estimated value
- $10,093,734
- Report date
- 24 Mar 2025
- Price
- $54.11
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Edgewise Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 443,792
- Estimated value
- $8,933,533
- Report date
- 03 Apr 2025
- Price
- $20.13
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 747,887
- Estimated value
- $8,107,095
- Report date
- 18 Feb 2025
- Price
- $10.84
- Ownership
- Indirect
Form 4 holding
10%+ Owner
PMV Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 4,975,291
- Estimated value
- $7,562,442
- Report date
- 23 Oct 2025
- Price
- $1.52
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Terns Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 755,635
- Estimated value
- $7,556,350
- Report date
- 16 Jul 2024
- Price
- $10.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
ArriVent Biopharma, Inc.
- Security class
- Common Stock
- Shares / value
- 1,513,664
- Estimated value
- $5,524,874
- Report date
- 30 Jan 2024
- Price
- $3.65
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Prelude Therapeutics Inc
- Security class
- Common Stock
- Shares / value
- 1,126,126
- Estimated value
- $4,999,999
- Report date
- 21 Apr 2026
- Price
- $4.44
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Acutus Medical, Inc.
- Security class
- Common Stock
- Shares / value
- 1,677,361
- Estimated value
- $2,616,683
- Report date
- 19 Jul 2021
- Price
- $1.56
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Traws Pharma, Inc.
- Security class
- Common Stock
- Shares / value
- 1,203,250
- Estimated value
- $2,009,427
- Report date
- 16 Apr 2026
- Price
- $1.67
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Passage BIO, Inc.
- Security class
- Common Stock
- Shares / value
- 6,066,343
- Estimated value
- $2,001,893
- Report date
- 26 Jun 2025
- Price
- $0.3300
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Arcutis Biotherapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 415,142
- Estimated value
- $1,469,935
- Report date
- 24 Jun 2022
- Price
- $3.54
- Ownership
- Indirect
Form 4 holding
Director
Janux Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 231,098
- Estimated value
- $1,356,545
- Report date
- 29 Dec 2021
- Price
- $5.87
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Homology Medicines, Inc.
- Security class
- Common Stock
- Shares / value
- 2,252,987
- Estimated value
- $1,286,681
- Report date
- 25 Mar 2024
- Price
- $0.5711
- Ownership
- By OrbiMed Private Investments VII, LP
Form 4 holding
10%+ Owner
Galecto, Inc.
- Security class
- Common Stock
- Shares / value
- 1,510,375
- Estimated value
- $1,132,781
- Report date
- 15 Aug 2023
- Price
- $0.7500
- Ownership
- Indirect
Form 4 holding
10%+ Owner
scPharmaceuticals Inc.
- Security class
- Common Stock
- Shares / value
- 252,858
- Estimated value
- $1,011,432
- Report date
- 13 Aug 2024
- Price
- $4.00
- Ownership
- Indirect
Form 4 holding
Director
Shattuck Labs, Inc.
- Security class
- Common Stock
- Shares / value
- 1,051,021
- Estimated value
- $911,970
- Report date
- 25 Aug 2025
- Price
- $0.8677
- Ownership
- Indirect
Form 4 holding
Director
Keros Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 45,057
- Estimated value
- $799,761
- Report date
- 21 Nov 2025
- Price
- $17.75
- Ownership
- Indirect
Form 4 holding
Director
ImageneBio, Inc.
- Security class
- Common Stock
- Shares / value
- 20,691
- Estimated value
- $716,833
- Report date
- 14 Apr 2026
- Price
- $2.49
- Ownership
- Indirect
Form 4 holding
Director
Repare Therapeutics Inc.
- Security class
- Common Stock
- Shares / value
- 96,190
- Estimated value
- $233,261
- Report date
- 07 Sep 2021
- Price
- $2.42
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Adicet Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 08 Apr 2026
- Price
- $6.52
- Ownership
- Indirect
Form 4 holding
Director
ALPINE IMMUNE SCIENCES, INC.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 18 May 2024
- Price
- $6.33
- Ownership
- Indirect
Form 4 holding
Director
ARS Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 26 Aug 2024
- Price
- $13.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Compass Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 09 Apr 2025
- Price
- $1.59
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Kinnate Biopharma Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 03 Apr 2024
- Price
- $2.59
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Theseus Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Feb 2024
- Price
- $3.05
- Ownership
- Indirect
Form 4 holding
Director
Turnstone Biologics Corp.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 08 Aug 2025
- Price
- $0.3590
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Xtant Medical Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 10 Apr 2025
- Price
- $0.4200
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Upstream Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 4,554,873
- Estimated value
- Report date
- 15 Oct 2024
- Price
- Ownership
- Indirect
Form 4 holding
Director
Shattuck Labs, Inc.
- Security class
- Common Warrants (right to buy)
- Shares / value
- 3,073,298
- Estimated value
- Report date
- 25 Aug 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Shattuck Labs, Inc.
- Security class
- Pre-Funded Warrants (right to buy)
- Shares / value
- 2,022,277
- Estimated value
- Report date
- 25 Aug 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Traws Pharma, Inc.
- Security class
- Series C Warrants (right to buy)
- Shares / value
- 1,793,187
- Estimated value
- Report date
- 16 Apr 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Traws Pharma, Inc.
- Security class
- Series A Warrants (right to buy)
- Shares / value
- 597,729
- Estimated value
- Report date
- 16 Apr 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Traws Pharma, Inc.
- Security class
- Series B Warrants (right to buy)
- Shares / value
- 597,729
- Estimated value
- Report date
- 16 Apr 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
ImageneBio, Inc.
- Security class
- Pre-Funded Warrants (right to buy)
- Shares / value
- 384,689
- Estimated value
- Report date
- 14 Apr 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Traws Pharma, Inc.
- Security class
- Pre-Funded Warrant (right to buy)
- Shares / value
- 96,348
- Estimated value
- Report date
- 29 Dec 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Traws Pharma, Inc.
- Security class
- Series A Warrant (right to buy)
- Shares / value
- 96,348
- Estimated value
- Report date
- 29 Dec 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
ALPINE IMMUNE SCIENCES, INC.
- Security class
- Warrant (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 11 Jan 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
ArriVent Biopharma, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 30 Jan 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
ArriVent Biopharma, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 30 Jan 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Corvus Pharmaceuticals, Inc.
- Security class
- Common Warrants (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 27 Jun 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Series A Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2024
- Price
- Ownership
- By OrbiMed Private Investments VII, LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Series B Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2024
- Price
- Ownership
- By OrbiMed Private Investments VII, LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Series C Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2024
- Price
- Ownership
- By OrbiMed Genesis Master Fund, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Sierra Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 01 Jul 2022
- Price
- $55.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Sierra Oncology, Inc.
- Security class
- Series A Warrants
- Shares / value
- 0
- Estimated value
- Report date
- 01 Jul 2022
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Sionna Therapeutics, Inc.
- Security class
- Series B convertible preferred stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Feb 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Sionna Therapeutics, Inc.
- Security class
- Series C convertible preferred stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Feb 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Third Harmonic Bio, Inc.
- Security class
- Series A-2 Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Sep 2022
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Third Harmonic Bio, Inc.
- Security class
- Series A-3 Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Sep 2022
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Third Harmonic Bio, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Sep 2022
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Tricida, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 25 Nov 2022
- Price
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Upstream Bio, Inc.
- Security class
- Series A redeemable convertible preferred stock
- Shares / value
- 0
- Estimated value
- Report date
- 15 Oct 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Upstream Bio, Inc.
- Security class
- Series B redeemable convertible preferred stock
- Shares / value
- 0
- Estimated value
- Report date
- 15 Oct 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Venetian-1 Acquisition Corp.
- Security class
- Simple Agreement for Future Equity
- Shares / value
- 0
- Estimated value
- Report date
- 01 Nov 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by ORBIMED ADVISORS LLC
4
SION
Sionna Therapeutics, Inc.
- Report period
- 07 May 2026
- Transactions
- 3
- Transaction value
- -$13,364,064
- Filing time
- 11 May 2026, 18:58
- Role
- Director
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 21 Apr 2026
- Transactions
- 2
- Transaction value
- +$12,499,999
- Filing time
- 23 Apr 2026, 18:48
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 17 Apr 2026
- Transactions
- 2
- Transaction value
- -$2,472,343
- Filing time
- 21 Apr 2026, 20:40
- Role
- Director
- Next action
- Open filing details
4
TRAW
Traws Pharma, Inc.
- Report period
- 16 Apr 2026
- Transactions
- 4
- Transaction value
- +$998,207
- Filing time
- 28 Apr 2026, 21:41
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IMA
ImageneBio, Inc.
- Report period
- 14 Apr 2026
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 16 Apr 2026, 19:23
- Role
- Director
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 14 Apr 2026
- Transactions
- 3
- Transaction value
- -$22,945,044
- Filing time
- 16 Apr 2026, 19:03
- Role
- Director
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 07 Apr 2026
- Transactions
- 4
- Transaction value
- -$674,847
- Filing time
- 09 Apr 2026, 17:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 02 Feb 2026
- Transactions
- 2
- Transaction value
- -$1,379,866
- Filing time
- 04 Feb 2026, 19:39
- Role
- Director
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 24 Dec 2025
- Transactions
- 1
- Transaction value
- -$1,486,010
- Filing time
- 29 Dec 2025, 20:44
- Role
- Director
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 17 Dec 2025
- Transactions
- 3
- Transaction value
- -$83,428
- Filing time
- 19 Dec 2025, 19:29
- Role
- Director
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 24 Nov 2025
- Transactions
- 3
- Transaction value
- -$4,814,205
- Filing time
- 26 Nov 2025, 18:45
- Role
- Director
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 21 Nov 2025
- Transactions
- 2
- Transaction value
- -$3,807,766
- Filing time
- 18 Dec 2025, 16:34
- Role
- Director
- Next action
- Open filing details
4
PMVP
PMV Pharmaceuticals, Inc.
- Report period
- 23 Oct 2025
- Transactions
- 1
- Transaction value
- -$1,520,000
- Filing time
- 27 Oct 2025, 17:19
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 08 Oct 2025
- Transactions
- 2
- Transaction value
- +$5,000,000
- Filing time
- 10 Oct 2025, 20:06
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PMVP
PMV Pharmaceuticals, Inc.
- Report period
- 10 Sep 2025
- Transactions
- 1
- Transaction value
- -$900,000
- Filing time
- 12 Sep 2025, 17:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 25 Aug 2025
- Transactions
- 6
- Transaction value
- +$5,471,826
- Filing time
- 02 Sep 2025, 21:52
- Role
- Director
- Next action
- Open filing details
3
STTK
Shattuck Labs, Inc.
- Report period
- 25 Aug 2025
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 02 Sep 2025, 21:48
- Role
- Director
- Next action
- Open filing details
4
TSBX
Turnstone Biologics Corp.
- Report period
- 08 Aug 2025
- Transactions
- 1
- Transaction value
- $0
- Filing time
- 12 Aug 2025, 17:22
- Role
- Director
- Next action
- Open filing details
4
IKNA
ImageneBio, Inc.
- Report period
- 25 Jul 2025
- Transactions
- 1
- Transaction value
- +$208,191
- Filing time
- 30 Jul 2025, 21:30
- Role
- Director
- Next action
- Open filing details
4
CRVS
Corvus Pharmaceuticals, Inc.
- Report period
- 27 Jun 2025
- Transactions
- 3
- Transaction value
- -$0.2552
- Filing time
- 01 Jul 2025, 21:23
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 24 Jun 2025
- Transactions
- 3
- Transaction value
- -$197,239
- Filing time
- 26 Jun 2025, 17:10
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 14 May 2025
- Transactions
- 2
- Transaction value
- -$2,665,333
- Filing time
- 16 May 2025, 17:26
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 24 Apr 2025
- Transactions
- 3
- Transaction value
- -$78,731
- Filing time
- 24 Apr 2025, 17:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 15 Apr 2025
- Transactions
- 3
- Transaction value
- -$49,704
- Filing time
- 17 Apr 2025, 18:10
- Role
- 10%+ Owner
- Next action
- Open filing details
4
XTNT
Xtant Medical Holdings, Inc.
- Report period
- 10 Apr 2025
- Transactions
- 2
- Transaction value
- -$30,708,129
- Filing time
- 14 Apr 2025, 19:14
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 09 Apr 2025
- Transactions
- 1
- Transaction value
- -$5,678,571
- Filing time
- 11 Apr 2025, 19:24
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
EWTX
Edgewise Therapeutics, Inc.
- Report period
- 03 Apr 2025
- Transactions
- 2
- Transaction value
- +$10,000,000
- Filing time
- 04 Apr 2025, 19:33
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 24 Mar 2025
- Transactions
- 3
- Transaction value
- -$310,483
- Filing time
- 26 Mar 2025, 19:00
- Role
- Director
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 19 Mar 2025
- Transactions
- 9
- Transaction value
- -$2,831,987
- Filing time
- 21 Mar 2025, 20:00
- Role
- Director
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 10 Mar 2025
- Transactions
- 15
- Transaction value
- -$16,965,596
- Filing time
- 12 Mar 2025, 21:34
- Role
- Director
- Next action
- Open filing details
4
MBX
MBX Biosciences, Inc.
- Report period
- 14 Feb 2025
- Transactions
- 4
- Transaction value
- +$2,020,756
- Filing time
- 19 Feb 2025, 17:52
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SION
Sionna Therapeutics, Inc.
- Report period
- 10 Feb 2025
- Transactions
- 4
- Transaction value
- +$9,900,000
- Filing time
- 10 Feb 2025, 16:28
- Role
- Director
- Next action
- Open filing details
3
SION
Sionna Therapeutics, Inc.
- Report period
- 06 Feb 2025
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 06 Feb 2025, 21:18
- Role
- Director
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 10 Jan 2025
- Transactions
- 3
- Transaction value
- -$142,223
- Filing time
- 14 Jan 2025, 17:17
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 06 Jan 2025
- Transactions
- 3
- Transaction value
- -$103,306
- Filing time
- 08 Jan 2025, 18:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TRAW
Traws Pharma, Inc.
- Report period
- 29 Dec 2024
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 27 Jan 2025, 19:03
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 20 Dec 2024
- Transactions
- 1
- Transaction value
- -$138,193
- Filing time
- 26 Dec 2024, 16:34
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 09 Dec 2024
- Transactions
- 3
- Transaction value
- -$51,988
- Filing time
- 11 Dec 2024, 17:32
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 04 Dec 2024
- Transactions
- 2
- Transaction value
- -$77,338
- Filing time
- 06 Dec 2024, 19:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Lomond Therapeutics Holdings, Inc.
- Report period
- 01 Nov 2024
- Transactions
- 13
- Transaction value
- +$9,999,997
- Filing time
- 05 Nov 2024, 18:02
- Role
- Director
- Next action
- Open filing details
3
Lomond Therapeutics Holdings, Inc.
- Report period
- 01 Nov 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 05 Nov 2024, 17:57
- Role
- Director
- Next action
- Open filing details
4
UPB
Upstream Bio, Inc.
- Report period
- 15 Oct 2024
- Transactions
- 8
- Transaction value
- +$14,025,000
- Filing time
- 17 Oct 2024, 16:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
UPB
Upstream Bio, Inc.
- Report period
- 10 Oct 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 10 Oct 2024, 20:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 19 Sep 2024
- Transactions
- 1
- Transaction value
- -$27,903
- Filing time
- 23 Sep 2024, 16:51
- Role
- 10%+ Owner
- Next action
- Open filing details
3
TRAW
Traws Pharma, Inc.
- Report period
- 16 Sep 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 23 Sep 2024, 16:42
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 16 Sep 2024
- Transactions
- 3
- Transaction value
- -$146,727
- Filing time
- 18 Sep 2024, 18:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MBX
MBX Biosciences, Inc.
- Report period
- 16 Sep 2024
- Transactions
- 7
- Transaction value
- +$12,000,000
- Filing time
- 17 Sep 2024, 20:13
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
MBX
MBX Biosciences, Inc.
- Report period
- 12 Sep 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 12 Sep 2024, 19:14
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SPRY
ARS Pharmaceuticals, Inc.
- Report period
- 26 Aug 2024
- Transactions
- 1
- Transaction value
- -$1,088,035
- Filing time
- 28 Aug 2024, 16:26
- Role
- Director
- Next action
- Open filing details
4
SPRY
ARS Pharmaceuticals, Inc.
- Report period
- 21 Aug 2024
- Transactions
- 4
- Transaction value
- -$11,497,963
- Filing time
- 23 Aug 2024, 18:38
- Role
- Director
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 13 Aug 2024
- Transactions
- 2
- Transaction value
- -$11,002,500
- Filing time
- 15 Aug 2024, 17:01
- Role
- Director
- Next action
- Open filing details
4
SCPH
scPharmaceuticals Inc.
- Report period
- 13 Aug 2024
- Transactions
- 2
- Transaction value
- +$2,000,000
- Filing time
- 15 Aug 2024, 16:51
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 15 Jul 2024
- Transactions
- 6
- Transaction value
- -$561,640
- Filing time
- 17 Jul 2024, 20:48
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TELA
TELA Bio, Inc.
- Report period
- 28 Jun 2024
- Transactions
- 3
- Transaction value
- -$2,022,000
- Filing time
- 02 Jul 2024, 16:54
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 17 Jun 2024
- Transactions
- 3
- Transaction value
- +$3,000,024
- Filing time
- 20 Jun 2024, 17:19
- Role
- Director
- Next action
- Open filing details
4
ALPINE IMMUNE SCIENCES, INC.
- Report period
- 18 May 2024
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 20 May 2024, 19:47
- Role
- Director
- Next action
- Open filing details
4
ELVN
Enliven Therapeutics, Inc.
- Report period
- 16 May 2024
- Transactions
- 2
- Transaction value
- -$22,877,262
- Filing time
- 20 May 2024, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CRVS
Corvus Pharmaceuticals, Inc.
- Report period
- 06 May 2024
- Transactions
- 2
- Transaction value
- +$2,499,856
- Filing time
- 08 May 2024, 20:28
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 01 May 2024
- Transactions
- 3
- Transaction value
- -$409,426
- Filing time
- 03 May 2024, 17:16
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 24 Apr 2024
- Transactions
- 1
- Transaction value
- -$25,041
- Filing time
- 26 Apr 2024, 17:01
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 19 Apr 2024
- Transactions
- 3
- Transaction value
- -$913,057
- Filing time
- 23 Apr 2024, 18:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 16 Apr 2024
- Transactions
- 3
- Transaction value
- -$238,231
- Filing time
- 18 Apr 2024, 17:10
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 11 Apr 2024
- Transactions
- 2
- Transaction value
- -$7,026,033
- Filing time
- 15 Apr 2024, 17:25
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 03 Apr 2024
- Transactions
- 5
- Transaction value
- $0
- Filing time
- 05 Apr 2024, 16:33
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3/A
TRAW
Traws Pharma, Inc.
- Report period
- 01 Apr 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 12 Apr 2024, 16:11
- Role
- Other*
- Next action
- Open filing details
3
TRAW
Onconova Therapeutics, Inc.
- Report period
- 01 Apr 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 03 Apr 2024, 19:56
- Role
- 10%+ Owner
- Next action
- Open filing details
3
QTTB
Homology Medicines, Inc.
- Report period
- 25 Mar 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 27 Mar 2024, 17:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 14 Feb 2024
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 14 Feb 2024, 16:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
AVBP
ArriVent Biopharma, Inc.
- Report period
- 30 Jan 2024
- Transactions
- 10
- Transaction value
- +$7,999,992
- Filing time
- 31 Jan 2024, 16:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 25 Jan 2024
- Transactions
- 3
- Transaction value
- +$7,500,000
- Filing time
- 26 Jan 2024, 19:14
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
AVBP
ArriVent Biopharma, Inc.
- Report period
- 25 Jan 2024
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 25 Jan 2024, 20:40
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
EWTX
Edgewise Therapeutics, Inc.
- Report period
- 23 Jan 2024
- Transactions
- 1
- Transaction value
- +$4,999,995
- Filing time
- 25 Jan 2024, 16:28
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ALPINE IMMUNE SCIENCES, INC.
- Report period
- 11 Jan 2024
- Transactions
- 2
- Transaction value
- +$1,850,498
- Filing time
- 16 Jan 2024, 16:39
- Role
- Director
- Next action
- Open filing details
4
ALPINE IMMUNE SCIENCES, INC.
- Report period
- 27 Dec 2023
- Transactions
- 6
- Transaction value
- -$28,671,734
- Filing time
- 29 Dec 2023, 16:18
- Role
- Director
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 18 Dec 2023
- Transactions
- 3
- Transaction value
- -$36,618
- Filing time
- 20 Dec 2023, 18:28
- Role
- Director
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 14 Dec 2023
- Transactions
- 3
- Transaction value
- -$24,584,100
- Filing time
- 15 Dec 2023, 18:04
- Role
- Director
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 12 Dec 2023
- Transactions
- 8
- Transaction value
- -$7,902,266
- Filing time
- 14 Dec 2023, 17:44
- Role
- Director
- Next action
- Open filing details
4
PMVP
PMV Pharmaceuticals, Inc.
- Report period
- 22 Nov 2023
- Transactions
- 1
- Transaction value
- -$195,763
- Filing time
- 24 Nov 2023, 16:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NPCE
NeuroPace Inc
- Report period
- 02 Oct 2023
- Transactions
- 2
- Transaction value
- -$75,449
- Filing time
- 04 Oct 2023, 17:36
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SPRY
ARS Pharmaceuticals, Inc.
- Report period
- 29 Aug 2023
- Transactions
- 1
- Transaction value
- +$3,100,000
- Filing time
- 31 Aug 2023, 17:26
- Role
- Director
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 15 Aug 2023
- Transactions
- 3
- Transaction value
- -$617,010
- Filing time
- 17 Aug 2023, 16:40
- Role
- 10%+ Owner
- Next action
- Open filing details
4/A
IKNA
Ikena Oncology, Inc.
- Report period
- 04 Aug 2023
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 21 Sep 2023, 17:02
- Role
- Director
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 31 Jul 2023
- Transactions
- 3
- Transaction value
- -$628,200
- Filing time
- 02 Aug 2023, 17:05
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 25 Jul 2023
- Transactions
- 3
- Transaction value
- -$114,464
- Filing time
- 27 Jul 2023, 16:28
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TSBX
Turnstone Biologics Corp.
- Report period
- 20 Jul 2023
- Transactions
- 6
- Transaction value
- +$4,999,992
- Filing time
- 24 Jul 2023, 16:38
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
TSBX
Turnstone Biologics Corp.
- Report period
- 20 Jul 2023
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 20 Jul 2023, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 17 Jul 2023
- Transactions
- 2
- Transaction value
- +$1,463,793
- Filing time
- 19 Jul 2023, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 13 Jul 2023
- Transactions
- 3
- Transaction value
- -$467,280
- Filing time
- 17 Jul 2023, 16:13
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 27 Jun 2023
- Transactions
- 4
- Transaction value
- +$1,828,750
- Filing time
- 29 Jun 2023, 16:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 27 Jun 2023
- Transactions
- 2
- Transaction value
- +$1,001,765
- Filing time
- 29 Jun 2023, 16:42
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 22 May 2023
- Transactions
- 1
- Transaction value
- +$4,999,999
- Filing time
- 24 May 2023, 17:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ELVN
Enliven Therapeutics, Inc.
- Report period
- 17 May 2023
- Transactions
- 2
- Transaction value
- +$9,095
- Filing time
- 19 May 2023, 16:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VRNA
Verona Pharma plc
- Report period
- 11 May 2023
- Transactions
- 4
- Transaction value
- -$9,938,132
- Filing time
- 15 May 2023, 18:07
- Role
- Director
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 04 May 2023
- Transactions
- 5
- Transaction value
- +$4,086,235
- Filing time
- 08 May 2023, 17:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 28 Apr 2023
- Transactions
- 9
- Transaction value
- +$3,673,901
- Filing time
- 02 May 2023, 21:34
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TELA
TELA Bio, Inc.
- Report period
- 19 Apr 2023
- Transactions
- 3
- Transaction value
- -$1,792,326
- Filing time
- 21 Apr 2023, 17:08
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 13 Apr 2023
- Transactions
- 9
- Transaction value
- -$128,257
- Filing time
- 17 Apr 2023, 17:28
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 10 Apr 2023
- Transactions
- 9
- Transaction value
- -$121,357
- Filing time
- 12 Apr 2023, 18:44
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GLTO
Galecto, Inc.
- Report period
- 05 Apr 2023
- Transactions
- 6
- Transaction value
- -$221,994
- Filing time
- 07 Apr 2023, 16:42
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ELVN
Enliven Therapeutics, Inc.
- Report period
- 23 Feb 2023
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 27 Feb 2023, 19:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 17 Feb 2023
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 23 Feb 2023, 13:16
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 15 Feb 2023
- Transactions
- 3
- Transaction value
- +$2,500,008
- Filing time
- 17 Feb 2023, 15:43
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IRON
Disc Medicine, Inc.
- Report period
- 29 Dec 2022
- Transactions
- 4
- Transaction value
- $0
- Filing time
- 03 Jan 2023, 20:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
IRON
Disc Medicine, Inc.
- Report period
- 29 Dec 2022
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 03 Jan 2023, 20:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 23 Dec 2022
- Transactions
- 1
- Transaction value
- +$1,000,000
- Filing time
- 28 Dec 2022, 16:57
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VRNA
Verona Pharma plc
- Report period
- 22 Dec 2022
- Transactions
- 5
- Transaction value
- -$136,000,855
- Filing time
- 27 Dec 2022, 16:38
- Role
- Director
- Next action
- Open filing details
4
SCPH
scPharmaceuticals Inc.
- Report period
- 25 Nov 2022
- Transactions
- 1
- Transaction value
- +$4,002,495
- Filing time
- 29 Nov 2022, 15:36
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Tricida, Inc.
- Report period
- 22 Nov 2022
- Transactions
- 3
- Transaction value
- -$2,205,635
- Filing time
- 25 Nov 2022, 19:13
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 08 Nov 2022
- Transactions
- 1
- Transaction value
- +$1,290,420
- Filing time
- 10 Nov 2022, 15:44
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 07 Nov 2022
- Transactions
- 1
- Transaction value
- +$1,000,320
- Filing time
- 09 Nov 2022, 15:25
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
THRD
Third Harmonic Bio, Inc.
- Report period
- 19 Sep 2022
- Transactions
- 5
- Transaction value
- +$5,100,000
- Filing time
- 21 Sep 2022, 18:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
EWTX
Edgewise Therapeutics, Inc.
- Report period
- 16 Sep 2022
- Transactions
- 1
- Transaction value
- +$4,999,999
- Filing time
- 16 Sep 2022, 16:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
THRD
Third Harmonic Bio, Inc.
- Report period
- 14 Sep 2022
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 14 Sep 2022, 18:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 12 Sep 2022
- Transactions
- 2
- Transaction value
- -$4,919,148
- Filing time
- 14 Sep 2022, 16:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 16 Aug 2022
- Transactions
- 6
- Transaction value
- +$8,929,800
- Filing time
- 18 Aug 2022, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
XTNT
Xtant Medical Holdings, Inc.
- Report period
- 15 Aug 2022
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 17 Aug 2022, 16:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 08 Aug 2022
- Transactions
- 2
- Transaction value
- -$10,464,363
- Filing time
- 10 Aug 2022, 16:22
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Sierra Oncology, Inc.
- Report period
- 01 Jul 2022
- Transactions
- 6
- Transaction value
- -$108,062,350
- Filing time
- 01 Jul 2022, 16:50
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ARQT
Arcutis Biotherapeutics, Inc.
- Report period
- 24 Jun 2022
- Transactions
- 2
- Transaction value
- -$7,287,402
- Filing time
- 28 Jun 2022, 16:29
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IKNA
Ikena Oncology, Inc.
- Report period
- 22 Jun 2022
- Transactions
- 4
- Transaction value
- -$1,128,021
- Filing time
- 24 Jun 2022, 17:39
- Role
- Director
- Next action
- Open filing details
4
PMVP
PMV Pharmaceuticals, Inc.
- Report period
- 26 May 2022
- Transactions
- 1
- Transaction value
- -$418,210
- Filing time
- 31 May 2022, 16:36
- Role
- 10%+ Owner
- Next action
- Open filing details
4
EWTX
Edgewise Therapeutics, Inc.
- Report period
- 18 May 2022
- Transactions
- 1
- Transaction value
- +$994,980
- Filing time
- 20 May 2022, 16:38
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 11 May 2022
- Transactions
- 3
- Transaction value
- +$420,482
- Filing time
- 13 May 2022, 17:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 06 May 2022
- Transactions
- 3
- Transaction value
- +$197,252
- Filing time
- 10 May 2022, 18:21
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 03 May 2022
- Transactions
- 2
- Transaction value
- +$1,016,285
- Filing time
- 05 May 2022, 17:23
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ARQT
Arcutis Biotherapeutics, Inc.
- Report period
- 06 Apr 2022
- Transactions
- 6
- Transaction value
- -$18,163,608
- Filing time
- 08 Apr 2022, 18:06
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PMVP
PMV Pharmaceuticals, Inc.
- Report period
- 29 Mar 2022
- Transactions
- 3
- Transaction value
- -$10,264,415
- Filing time
- 31 Mar 2022, 17:30
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 11 Feb 2022
- Transactions
- 4
- Transaction value
- +$1,989,446
- Filing time
- 15 Feb 2022, 20:42
- Role
- Director
- Next action
- Open filing details
4
Sierra Oncology, Inc.
- Report period
- 26 Jan 2022
- Transactions
- 6
- Transaction value
- +$6,434,340
- Filing time
- 28 Jan 2022, 20:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ETNB
89bio, Inc.
- Report period
- 25 Jan 2022
- Transactions
- 4
- Transaction value
- -$592,384
- Filing time
- 27 Jan 2022, 16:22
- Role
- 10%+ Owner
- Next action
- Open filing details
4/A
PASG
Passage BIO, Inc.
- Report period
- 20 Jan 2022
- Transactions
- 1
- Transaction value
- +$254,000
- Filing time
- 05 May 2022, 17:11
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 19 Jan 2022
- Transactions
- 3
- Transaction value
- +$1,578,717
- Filing time
- 21 Jan 2022, 18:18
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 14 Jan 2022
- Transactions
- 3
- Transaction value
- +$905,205
- Filing time
- 20 Jan 2022, 17:03
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PASG
Passage BIO, Inc.
- Report period
- 11 Jan 2022
- Transactions
- 3
- Transaction value
- +$841,082
- Filing time
- 13 Jan 2022, 18:37
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 11 Jan 2022
- Transactions
- 4
- Transaction value
- +$442,750
- Filing time
- 13 Jan 2022, 18:18
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
JANX
Janux Therapeutics, Inc.
- Report period
- 29 Dec 2021
- Transactions
- 2
- Transaction value
- -$820,120
- Filing time
- 30 Dec 2021, 20:00
- Role
- Director
- Next action
- Open filing details
4
JANX
Janux Therapeutics, Inc.
- Report period
- 21 Dec 2021
- Transactions
- 2
- Transaction value
- -$2,268,600
- Filing time
- 23 Dec 2021, 15:13
- Role
- Director
- Next action
- Open filing details
4
JANX
Janux Therapeutics, Inc.
- Report period
- 16 Dec 2021
- Transactions
- 2
- Transaction value
- -$7,500,231
- Filing time
- 17 Dec 2021, 16:13
- Role
- Director
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 10 Dec 2021
- Transactions
- 1
- Transaction value
- +$2,999,990
- Filing time
- 14 Dec 2021, 17:41
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Tricida, Inc.
- Report period
- 15 Nov 2021
- Transactions
- 2
- Transaction value
- +$4,000,002
- Filing time
- 17 Nov 2021, 15:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 04 Nov 2021
- Transactions
- 2
- Transaction value
- +$18,750,000
- Filing time
- 08 Nov 2021, 20:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 12 Oct 2021
- Transactions
- 7
- Transaction value
- +$10,000,000
- Filing time
- 14 Oct 2021, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
Theseus Pharmaceuticals, Inc.
- Report period
- 06 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 06 Oct 2021, 19:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CRVS
Corvus Pharmaceuticals, Inc.
- Report period
- 20 Sep 2021
- Transactions
- 1
- Transaction value
- -$6,757,732
- Filing time
- 22 Sep 2021, 17:27
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ALPINE IMMUNE SCIENCES, INC.
- Report period
- 17 Sep 2021
- Transactions
- 2
- Transaction value
- +$9,499,988
- Filing time
- 21 Sep 2021, 18:42
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 03 Sep 2021
- Transactions
- 4
- Transaction value
- -$274,794
- Filing time
- 08 Sep 2021, 18:18
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 31 Aug 2021
- Transactions
- 6
- Transaction value
- -$1,290,550
- Filing time
- 02 Sep 2021, 20:27
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 26 Aug 2021
- Transactions
- 6
- Transaction value
- -$615,748
- Filing time
- 30 Aug 2021, 18:37
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 23 Aug 2021
- Transactions
- 6
- Transaction value
- -$622,426
- Filing time
- 25 Aug 2021, 20:43
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 17 Aug 2021
- Transactions
- 4
- Transaction value
- -$693,210
- Filing time
- 19 Aug 2021, 20:55
- Role
- Director
- Next action
- Open filing details
4
XTNT
Xtant Medical Holdings, Inc.
- Report period
- 15 Aug 2021
- Transactions
- 2
- Transaction value
- $0
- Filing time
- 17 Aug 2021, 17:58
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
AFIB
Acutus Medical, Inc.
- Report period
- 19 Jul 2021
- Transactions
- 2
- Transaction value
- +$14,999,992
- Filing time
- 21 Jul 2021, 17:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4/A
ELVN
IMARA Inc.
- Report period
- 16 Jul 2021
- Transactions
- 1
- Transaction value
- +$9,999,996
- Filing time
- 23 Jul 2021, 17:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 01 Jul 2021
- Transactions
- 1
- Transaction value
- -$1,356,675
- Filing time
- 06 Jul 2021, 16:42
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 28 Jun 2021
- Transactions
- 1
- Transaction value
- -$553,775
- Filing time
- 30 Jun 2021, 21:01
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 23 Jun 2021
- Transactions
- 3
- Transaction value
- -$4,824,541
- Filing time
- 25 Jun 2021, 19:11
- Role
- 10%+ Owner
- Next action
- Open filing details
4
JANX
Janux Therapeutics, Inc.
- Report period
- 15 Jun 2021
- Transactions
- 8
- Transaction value
- +$11,999,501
- Filing time
- 16 Jun 2021, 18:17
- Role
- Director
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 10 Jun 2021
- Transactions
- 1
- Transaction value
- -$2,625,197
- Filing time
- 14 Jun 2021, 17:58
- Role
- 10%+ Owner
- Next action
- Open filing details
3
JANX
Janux Therapeutics, Inc.
- Report period
- 10 Jun 2021
- Transactions
- 0
- Transaction value
- $0
- Filing time
- 10 Jun 2021, 19:35
- Role
- Director
- Next action
- Open filing details
4
SWTX
SpringWorks Therapeutics, Inc.
- Report period
- 07 Jun 2021
- Transactions
- 3
- Transaction value
- -$4,101,908
- Filing time
- 09 Jun 2021, 18:26
- Role
- 10%+ Owner
- Next action
- Open filing details